ArticleNeuroradiology2026
Carotid web in patients with embolic stroke of undetermined source undergoing endovascular therapy for anterior circulation large vessel occlusion.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveCarotid web (CaW) is an emerging cause of embolic stroke of undetermined source (ESUS), yet its prevalence and clinical implications among ESUS patients presenting with anterior circulation intracranial large vessel occlusion (LVO) treated with endovascular therapy (EVT) remain unclear.
methodsWe conducted a multicenter retrospective cohort study across three tertiary stroke centers, consecutively enrolling adults with acute ischemic stroke due to anterior circulation intracranial LVO (M1/M2) who underwent EVT between January 2017 and November 2025. ESUS was diagnosed after standardized etiologic workup. CaW was assessed on vascular imaging by two blinded neuroradiologists. Patients were stratified into CaW + and non-CaW ESUS groups. Baseline characteristics, procedural parameters, and 90-day functional outcomes assessed by the modified Rankin Scale (mRS) were compared.
resultsAmong 1170 EVT-treated anterior circulation LVO patients, 263 (22.5%) met ESUS criteria, of whom 40 (15.2%) had ipsilateral CaW. Patients with CaW were more frequently female (52.5% vs. 31.4%; P = 0.047), while baseline NIHSS, ASPECTS, occlusion distribution, reperfusion rates and hemorrhagic complications were similar. Favorable 90-day outcome was more frequent in the CaW-positive group (87.5% vs. 55.2%; P < 0.001). During a median follow-up of 18 months, recurrent ischemic stroke occurred in 28.0% (7/25) of medically treated CaW patients, whereas no recurrence was observed after carotid revascularization.
conclusionsIpsilateral CaW was identified in approximately 15% of EVT-treated ESUS patients with anterior circulation intracranial LVO and was associated with better functional outcomes without increased hemorrhagic risk. High recurrence under medical therapy warrants prospective evaluation of optimal secondary prevention strategies.
Indexed as
Identifiers
42371034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.